PRLD · Prelude Therapeutics Inc
$4.06
-0.14 (-3.33%)
At close · Jul 20
Market Cap
$323.36M
Shares
79.65M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.06
Open$4.24
Day$3.95–4.32
52W$0.75–5.69
Avg vol 30d473K
Short int2.8M · 3.5% float · 3.5d
Short vol70%
Last earningsMar 10, 2026
DataSep 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+36%
above
Price vs 50-day avg
−8%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
67%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+100%
trailing
YTD return
+40%
this year
Relative strength
+93%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Flat
1 of 55 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.54% of float · ▲ +57.4% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+73%
Y/Y
EPS growth
+23%
Y/Y
Free cash flow
$-56.4M
Balance sheet
$35.3M
net cash
Quant / Vol
risk profile
Volatility
197%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
9.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+36%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
67%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Flat
1 of 55 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.54% of float · ▲ +57.4% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $4 · 67%
52-wk high $6
vs 200-day avg +36%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, restricted cash and marketable securities | $84.8M | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRLD
this stock
Prelude Therapeutics Inc
|
$323.36M | +40.0% | +73.4% | — | 3.5% |
|
ONC
BeOne Medicines Ltd.
|
$448.86B | +2.2% | +22179.2% | 913.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.95B | +6.0% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.47B | -12.8% | +20.8% | 16.4 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +0.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRLD | -8.6% | -6.0% | +100.0% | -23.8% | +40.0% |
| SPY | -1.0% | -0.6% | +7.1% | -0.6% | +8.8% |
| vs SPY | -7.6% | -5.4% | +92.9% | -23.2% | +31.2% |